Nu Skin Enterprises Company Profile (NYSE:NUS)

Nu Skin Enterprises trades on the New York Stock Exchange (NYSE) under the ticker symbol "NUS."

Nu Skin Enterprises declared a quarterly dividend on Thursday, August 3rd. Stockholders of record on Friday, August 25th will be paid a dividend of $0.36 per share on Wednesday, September 13th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 2.25%. The ex-dividend date of this dividend is Wednesday, August 23rd. View Nu Skin Enterprises' Dividend History.

Nu Skin Enterprises, Inc. (NYSE:NUS) released its earnings results on Wednesday, August, 2nd. The company reported $0.77 earnings per share for the quarter, topping analysts' consensus estimates of $0.69 by $0.08. The company earned $550.10 million during the quarter, compared to the consensus estimate of $548.09 million. Nu Skin Enterprises had a net margin of 7.53% and a return on equity of 24.14%. The company's revenue was down 8.4% compared to the same quarter last year. During the same period last year, the firm posted $0.79 earnings per share. View Nu Skin Enterprises' Earnings History.

Nu Skin Enterprises is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Nu Skin Enterprises.

Nu Skin Enterprises updated its third quarter earnings guidance on Thursday, October, 12th. The company provided earnings per share (EPS) guidance of $0.74-0.76 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.77. The company issued revenue guidance of $559-563 million, compared to the consensus revenue estimate of $559.04 million.

6 brokerages have issued 12-month price targets for Nu Skin Enterprises' stock. Their forecasts range from $50.00 to $80.00. On average, they expect Nu Skin Enterprises' stock price to reach $60.67 in the next year. View Analyst Ratings for Nu Skin Enterprises.

Here are some recent quotes from research analysts about Nu Skin Enterprises stock:

• 1. According to Zacks Investment Research, "Nu Skin is a premier anti-aging company. The company's anti-aging products feature the ageLOC line of products including ageLOC Tru Face Essence Ultra firming serum, the ageLOC TR90 weight management and body shaping system, ageLOC R2 nutritional supplement, and ageLOC Transformation daily skin care system. " (10/17/2017)
• 2. Pivotal Research analysts commented, "We think that weighed on the shares after hours but the company did a fine job of explaining the sharp shift in EPS and sales to the 4Q. In the 4Q17, they expect LTO sales of $100 million, with none in the 2Q or 3Q. Last year there were $106 million of LTO sales in the 2Q and $56 million in the 3Q so that is the tough comp we face this year in the 2Q and 3Q, and the easy comp in 4Q. The company shrunk its share base by 4.2% Y/Y, more aggressive than the normal 2%-3% share shrink. Yet, only acquired $7 million of shares in the 1Q. New CFO Mark Lawrence affirmed his support of the company’s capital allocation policy. At quarter end the company had only $81 million of net debt." (5/4/2017)
• 3. Jefferies Group LLC analysts commented, "Last night, NUS reported 4Q results. Despite an early December update, 4Q revenue still missed the low end of guidance by ~$19m (-3.4%), well below street estimates (-5.2%, -$29m). An unexpected +$0.10 tax add-back helped EPS reach the guidance midpoint (in-line with consensus). 1Q revenue/EPS -2.6% and -11% below the street (midpoint) may weigh on the stock, but reaffirming FY guidance suggests an optimistic outlook for LumiSpa in 4Q' 1Q guidance below the street may weigh on shares near-term. Although management reaffirmed its FY guidance, 1Q revenue of $480-500m (implied 3-8% CC growth) is just below the street at the high end (consensus $503m), and -2.6% below at the midpoint. EPS guidance of $0.47-0.51 is -$0.06 (-11%) below consensus at the midpoint. This weak 1Q guidance, combined with the 4Q revenue miss, may weigh on the shares nearterm. However with FY guidance re-affirmed, easing comps in 2H, and an expected launch of LumiSpa in October, the back half of 2017 sets up for accelerating revenue growth, which could prove to be an upside catalyst for the stock." (2/17/2017)

Some companies that are related to Nu Skin Enterprises include Energizer Holdings (EPC), Matthews International Corporation (MATW), USANA Health Sciences (USNA), PZ Cussons plc (PZC), Revlon (REV), Avon Products (AVP), Nautilus (NLS), KP Tissue (KPT), Swallowfield plc (SWL), Blackmores Limited (BKL), DS Healthcare Group (DSKX), L'Oreal SA (OR) and Litebulb Group Ltd (LBB).

Nu Skin Enterprises' management team includes the folowing people:

• Steven J. Lund, Executive Chairman of the Board
• Ryan S. Napierski, President
• Ritch N. Wood, Chief Executive Officer
• Mark H. Lawrence, Chief Financial Officer
• Joseph Y. Chang Ph.D., Executive Vice President - Product Development, Chief Scientific Officer
• D. Matthew Dorny, General Counsel, Secretary
• Daniel W. Campbell, Lead Independent Director
• Nevin N. Andersen, Independent Director
• Andrew D. Lipman, Independent Director
• Neil H. Offen, Independent Director

Shares of Nu Skin Enterprises can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Nu Skin Enterprises stock can currently be purchased for approximately $63.96.